GlobeNewswire by notified

Philips extends its mobile C-arm range with Zenition 30, alleviating staff shortages by empowering surgeons with greater personalization and control

Share

September 13, 2023

  • Offering surgeons greater flexibility, control, and personalization in C-arm operation and image acquisition, Philips’ new Zenition 30 reduces dependency on technician support for a wide variety of minimally invasive procedures  
  • Advanced imaging algorithms contribute to outstanding image quality and dose efficiency

Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Image Guided Therapy Mobile C-arm System 3000 – Zenition 30 [1], the latest addition to the company’s highly versatile Zenition mobile C-arm series. Mobile C-arms are X-ray systems that are brought into the operating room (OR) to provide live image guidance during a wide range of clinical procedures which include orthopedics, trauma, spine, pain management and other surgical procedures.

The Zenition 30 gives surgeons a greater level of control, empowering them to work more autonomously and independently. By reducing dependency on support staff, Zenition 30 helps alleviate the staff shortages faced by many hospitals, while its workflow-enhancing features and excellent image quality allow surgeons to deliver high-quality care to more patients. The launch of the Zenition 30 follows the recent launch of the Philips Zenition 10 C-arm [2].

“Based on our Zenition platform’s proven ease of use and workflow efficiency, the new Zenition 30 offers a unique combination of personalized control and image clarity to enhance the speed and accuracy of decision-making for a range of clinical procedures at a price point that meets today’s economic and business goals,” said Mark Stoffels, General Manager, Philips Image Guided Therapy Systems.

High-quality imaging
Zenition 30 offers versatility for a range of clinical procedures which include orthopedics, trauma, spine, pain management and other surgical procedures. Featuring Philips’ latest-generation flat detector technology, advanced imaging algorithms, and personalized user profiles, the new system delivers superior image quality, dose efficiency, and workflow customization. From the moment a surgeon logs on, the Zenition 30 automatically adjusts to their preferred settings and way of working, contributing to fewer manual adjustments and more first-time-right imaging. In addition to rapid set-up and protocol selection, the Zenition 30 also offers surgeons much greater control over C-arm positioning during surgical procedures.

In independent usability studies involving clinicians around the world who were offered hands-on experience of the Zenition 30 in simulated environments, 95% said they believed its enhanced surgeon control would allow them to work independently [3], while 84% believed that Zenition 30’s personalized image quality profiles meant fewer images might be needed during a procedure because the first image already incorporates their preferred settings [4].

As part of its commitment to doing business sustainably and helping its customers make responsible choices, Philips has designed the Zenition 30 to have a 25% increased product lifetime [5] and also has a refurbished program available, making it ‘circular-ready’ for repair, refurbishment, and recycling [5].

Other C-arm systems in Philips’ Zenition series are the Zenition 50, Zenition 70, and the recently launched Zenition 10 [2].

[1] Zenition 30 mobile C-arm systems are available for sale in a limited number of countries. Please check with a local representative for availability in your market. Pending 510 (k) not available for sale in the USA.
[2] Zenition 10 mobile C-arm system is not available in the USA.
[3] Results were obtained during a claims substantiation study performed in February and September 2022 by Use-Lab GmbH, an independent company. Response is based on 37 clinicians around the world, who answered a questionnaire subsequent to a usability study with additional hands-on time with the system.
[4] Results were obtained during a claims substantiation study performed in February and September 2022 by Use-Lab GmbH, an independent company. Response is based on 50 clinicians around the world, who answered a questionnaire subsequent to a usability study with additional hands-on time with the system.
[5] Compared to its predecessor, BV Endura 2.3.

For further information, please contact:

Joost Maltha 
Philips Global Press Office 
Tel: +31 6 10 55 8116  
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 71,500 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®29.9.2023 22:06:00 CEST | Press release

TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. TOFIDENCE is the first tocilizumab biosimilar approved in the United States. Biosimilars are biologic products that have been demonstrated to have equivalent efficacy and comparable safety as the approved reference product, with the advantage that they may offer cost savings and promote

Monument Reports Fourth Quarter and Fiscal 2023 Results29.9.2023 21:26:28 CEST | Press release

Gross Revenue of US$12.39 Million and Cash Cost of US$917/Oz for Gold Sulphide Production and US$1,622/Oz for Gold Oxide Production VANCOUVER, British Columbia, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its annual financial results for the year ended June 30, 2023. All amounts are in United States dollars unless otherwise indicated (refer to www.sedar.com for full financial results). Cathy Zhai, the President and CEO commented, “Fiscal 2023 was a milestone year for the Company with the gold sulphide project completed, and the flotation plant was put into production at the Selinsing Gold Mine in Malaysia. The commercial production has also been reached in August 2023 subsequent to the year end. It again demonstrates Monument has been able to deliver what’s been promised and now we are ready for the next corporate move.” Fiscal Year 2023 Highlights: Construction of the Selinsing sulphide flotation pla

Nokia Corporation: Repurchase of own shares on 29.09.202329.9.2023 20:00:00 CEST | Press release

Nokia Corporation Stock Exchange Release 29 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 29.09.2023 Espoo, Finland – On 29 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL319,5513.57CEUX58,3773.57AQEU11,0113.57TQEX4,7613.57Total393,7003.57 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 Januar

EPH European Property Holdings PLC announces Unaudited Interim Results for the Six Months to 30 June 2023 and appointment of Management Committee Members29.9.2023 19:00:00 CEST | Press release

29 September 2023, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR BUSINESS HIGHLIGHTS FIRST HALF YEAR OF 2023 With an established portfolio of high-quality properties in prime locations in Europe occupied by tenants with strong credit ratings, combined with professional asset management, EPH European Property Holdings PLC (“EPH” or the “Company”) has demon-strated operational stability in the first six months of 2023, despite the ongoing market environment challenges. As a result, EPH not only achieved almost full occupancy throughout its European portfolio, it also increased rental income.The sale of the Company’s Russian portfolio was concluded in April 2023, following the Extraordinary General Meeting (held on 1 November 2022) at which the shareholders of EPH authorised the Board of Directors to sell EPH Group’s entire Russian property portfolio by way of a management buyout. Upon disposal of the Russian segment in the first half of 2023, the Company reclassified the

Oxurion Publishes First Half 2023 Results29.9.2023 19:00:00 CEST | Press release

Regulated Information Leuven, BELGIUM, Boston, MA, US –September 29, 2023 – 7.00PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2023. The half-year report is available in the “Investors” section of the Company’s website and can also be downloaded as a PDF. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel